Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs SYSCO Corporation (SYY) Price & Performance

Bio-Rad Laboratories, Inc. Class A Common StockTrade
SYSCO CorporationTrade

Price performance (Past 24H)

Key statistics

Bio-Rad Laboratories, Inc. Class A Common Stock vs SYSCO Corporation — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while SYSCO Corporation trades at $83.48 (market cap $39.62B). The key difference: SYSCO Corporation is far larger — about 4.9× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and SYSCO Corporation pays a 2.66% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.

BIOSYY
Market Cap
$8.04B$39.62B
Sector
HealthConsumer Staples
52-Week High
$339.75$91.16
52-Week Low
$241.71$69.30
Enterprise Value
$7.85B$53.10B
Dividend Yield
2.66%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bio-Rad Laboratories, Inc. Class A Common Stock

BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.

Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.

SYSCO Corporation

Sysco Corporation (SYY) trades at $83.46, down 0.44% on the day, with a bullish technical signal and positive analyst sentiment. The stock shows strong fundamentals with consistent revenue growth reaching $81.37B in 2025 and a net income margin of 2.08%. Recent earnings beat expectations in Q3 and Q4 2025, though Q1 2026 slightly missed. The company maintains solid cash flow generation and recently announced a $0.55 dividend payable in July 2026.

Sysco's outlook remains favorable with 60% analyst buy ratings and a consensus price target of $83.67, slightly above current levels. Key opportunities include sustained revenue growth and operational efficiencies, while risks involve margin pressure and competitive industry dynamics. The stock presents a balanced investment case with moderate upside potential amid stable cash flows.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.

Read more on BIO

About SYSCO Corporation

Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.

Read more on SYY